Table 4.
Clinical trials of convalescent plasma transfusion in patients with COVID-19Searched on http://www.chictr.org.cn/ and https://clinicaltrials.gov/. As of March 15, 2020.
| Register number | Title | Group 1 (sample size) | Group 2 (sample size) | Primary indicator | Primary sponsor |
|---|---|---|---|---|---|
| ChiCTR2000030039 | Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) | Conventional therapy with infusion of convalescent plasma: 200-500 mL (30 patients) | Conventional therapy (30 patients) | Viral load, SARS-CoV-2 antibody levels | Affiliated Hospital of Xuzhou Medical University |
| ChiCTR2000029757 | Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial | Conventional treatment and convalescent plasma therapy (100 patients) | Conventional treatment (100 patients) | Number of days between randomized grouping and clinical improvement | China-Japan Friendship Hospital |
| ChiCTR2000029850 | Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19) | Standardized comprehensive treatment combined with convalescent plasma treatment (10 patients) | Standardized comprehensive treatment (10 patients) | Fatality rate | The First Affiliated Hospital of Zhejiang University School of Medicine |
| ChiCTR2000030010 | A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) | Anti-SARS-CoV-2 virus-inactivated plasma (50 patients) | Ordinary plasma (50 patients) | Improvement of clinical symptoms | Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) |
| ChiCTR2000030046 | A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19) | Anti-2019-nCoV virus-inactivated plasma (10 patients) | Changes to clinical symptoms, laboratory and radiological data | First People's Hospital of Jiangxia District | |
| ChiCTR2000030179 | Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) | Routine treatment + plasma treatment (50 patients) | Routine treatment (50 patients) | Cure rate, mortality | The First Affiliated Hospital of Nanchang University |
| ChiCTR2000030381 | A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2-inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient | Conventional treatment and anti-SARS-CoV-2 virus-inactivated plasma (20 patients) | Conventional treatment and ordinary plasma (20 patients) | Clinical symptom improvement | First People's Hospital of Jiangxi District, Wuhan |
| ChiCTR2000030627 | Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases | Convalescent plasma therapy + routine treatment (15 patients) | Routine treatment (15 patients) | Temperature, virus nucleic acid detection | The First Affiliated Hospital of Zhengzhou University |
| ChiCTR2000030702 | Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial | Conventional treatment and convalescent plasma therapy (25 patients) | Conventional treatment (25 patients) | Time to clinical recovery after randomization | China-Japan Friendship Hospital |
| NCT04292340 | Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19 | Anti-SARS-CoV-2-inactivated convalescent plasma | Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions | Shanghai Public Health Clinical Center |